Cytodyn Inc (CYDY)

[The Lawman]

Mr. Pearsby:

You are continuing to miss the point regarding PRO 140.

Yes, HAART drugs work, and help suppress viral load, although most suffer from resistance over time.

However, the problem with HAART drugs,in addition to resistance over time, is that they have toxic side effects.

Read the label of any HAART drug, and you will see a very long list of side effects, and possible toxicities.

As with HAART drugs, PRO 140 also suppresses viral load.

However, unlike HAART drugs, PRO 140 suppresses viral load without any toxicity or side effects, other than minor discomfort at the injection site.

This is a HUGE advantage that PRO 140 has over all HAART drugs.

If the Phase II and IIB results for PRO 140 are borne out in the ongoing Phase III pivotal monotherapy trial, and gets FDA approval for this indication, PRO 140 will likely become the standard of care in a multi-billion dollar industry for HIV drugs.

In that event, Cytodyn will be worth many times more than its current value.

In the meantime, Cytodyn's likely approval for use of PRO 140 in combination with failed HAART drugs, which is late in that study, should enhance interest in Cytodyn from both investors and possible suitors.

Finally, I think many would appreciate it if you would finally come clean about your agenda, and an admission that you are short, rather than long, the stock.

LM